A decision support framework for genomically informed investigational cancer therapy.
暂无分享,去创建一个
Amber M. Johnson | Ann M. Bailey | G. Mills | E. Bernstam | F. Meric-Bernstam | M. Davies | Ken Chen | R. Broaddus | S. Kopetz | D. Hong | A. Bailey | Jia Zeng | L. Brusco | V. Holla | J. Mendelsohn | M. Routbort | K. Patel | S. Piha-Paul | A. Eterovic | A. Tsimberidou | K. Shaw | M. Davies | Vijaykumar Holla | A. K. Eterovic | Lauren Brusco
[1] Christian A. Rees,et al. Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.
[2] Joshua M. Stuart,et al. Integrating genotype and phenotype information: an overview of the PharmGKB project , 2001, The Pharmacogenomics Journal.
[3] Russ B. Altman,et al. PharmGKB: the Pharmacogenetics Knowledge Base , 2002, Nucleic Acids Res..
[4] G. Daley,et al. Genetic complementation of cytokine signaling identifies central role of kinases in hematopoietic cell proliferation , 2004, Oncogene.
[5] M. Stratton,et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.
[6] Max S Wicha,et al. Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.
[7] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.
[8] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[9] Leyla Isik,et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. , 2009, Cancer research.
[10] G. Hortobagyi,et al. Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes , 2009, Clinical Cancer Research.
[11] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[12] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[13] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[14] Daniel Rios,et al. Bioinformatics Applications Note Databases and Ontologies Deriving the Consequences of Genomic Variants with the Ensembl Api and Snp Effect Predictor , 2022 .
[15] J. Desai,et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. , 2010 .
[16] C. Sander,et al. Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.
[17] P. Febbo,et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[18] A. Gonzalez-Perez,et al. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. , 2011, American journal of human genetics.
[19] John V Heymach,et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. , 2012, Journal of the National Cancer Institute.
[20] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[21] H. Hakonarson,et al. Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing , 2013, Genome Medicine.
[22] M. Ladanyi,et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. , 2012, Cancer discovery.
[23] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[24] Buzhou Tang,et al. Identifying the status of genetic lesions in cancer clinical trial documents using machine learning , 2012, BMC Genomics.
[25] F. Bosch,et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.
[26] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[27] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[28] Lynda Chin,et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.
[29] Arul M Chinnaiyan,et al. Advancing precision medicine for prostate cancer through genomics. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Schadendorf,et al. TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.
[31] Matthew S. Lebo,et al. A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record , 2013, Genetics in Medicine.
[32] G. Mills,et al. CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features , 2013, PloS one.
[33] Marc S. Williams,et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.
[34] Benjamin Haibe-Kains,et al. Inconsistency in large pharmacogenomic studies , 2013, Nature.
[35] William Pao,et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.
[36] James X. Sun,et al. Abstract 1893: A computational method for somatic versus germline variant status determination from targeted next-generation sequencing of clinical cancer specimens without a matched normal control , 2014 .
[37] W. Hahn,et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. , 2014, The Journal of molecular diagnostics : JMD.
[38] A. McKenna,et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.
[39] Elmer V. Bernstam,et al. Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy , 2014, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.
[40] Dennis C. Friedrich,et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.
[41] Jane C Weeks,et al. Physicians' attitudes about multiplex tumor genomic testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] E. Mardis,et al. Prioritizing targets for precision cancer medicine. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] J. Valcárcel,et al. Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers , 2014, Cell.
[44] D. Berry,et al. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[45] Ken Chen,et al. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. , 2014, Discovery medicine.
[46] James X. Sun,et al. Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer , 2014, Clinical Cancer Research.
[47] Adam Kiezun,et al. Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.
[48] Heidi L Rehm,et al. Return of genomic results to research participants: the floor, the ceiling, and the choices in between. , 2014, American journal of human genetics.